Immunotherapy as a Downstaging Therapy for Liver Transplantation
Birgit Schwacha‐Eipper, Iulia Minciună, Vanessa Banz, Jean‐François Dufour
Abstract
Locoregional therapies are downstaging methods for patients with hepatocellular carcinoma (HCC) outside Milan criteria. Sorafenib was the first systemic therapy tested in a neoadjuvant setting of liver transplantation, but with unsatisfactory results due to minimal response rate(1). Recently, immune checkpoint inhibitors have been shown to control HCC in a significant fraction of patients and to even induce complete response (2).
Topics & Concepts
MedicineLiver transplantationImmunotherapyTransplantationIntensive care medicineInternal medicineCancerLiver Disease Diagnosis and TreatmentLiver Disease and TransplantationOrgan Transplantation Techniques and Outcomes